Despite its ability to induce apoptosis, several tumors are resistant to TNF*α*-mediated apoptosis.^[@bib1]^ This resistance has been attributed to TNF*α*-mediated NF-*κ*B activation as blockade of NF-*κ*B sensitizes cells to TNF*α*-induced cell death.^[@bib2],\ [@bib3]^ Some anti-cancer chemotherapeutic drugs in combination with TNF*α* can kill resistant tumor cells.^[@bib4]^ Glioblastoma multiforme (GBM) -- the most aggressive malignant brain tumor, is largely resistant to current therapeutic regimens. We have reported that organoselenium Ebselen sensitizes glioma cells to TNF*α*-induced apoptosis by abrogating NF-*κ*B activation.^[@bib5]^

Casein kinase-2 (CK2)-- a protein kinase important for cell survival and resistance to apoptosis,^[@bib6]^ is over-expressed in several malignancies.^[@bib7]^ CK2 negatively regulates caspase activity^[@bib8]^ and CK2 inhibitors (CK2-Is) increase the susceptibility of cancer cells to chemotherapeutic agents or apoptotic stimuli.^[@bib9]^ CK2 inhibitor, DRB, sensitizes tumor cells to TRAIL (TNF*α*-related apoptosis inducing ligand)-induced apoptosis.^[@bib10]^ CK2 inhibitor, Apigenin, inhibits NF-*κ*B activation in breast cancer cell lines^[@bib11]^ and DRB enhances Apo2L/TRAIL-induced glioma cell death.^[@bib12]^ CK2-I blocks TNF*α*-induced p65 phosphorylation^[@bib13]^ and reduces constitutive NF-*κ*B activity in breast cancer cells.^[@bib14]^ TNF*α*-activated NF-*κ*B represses p53 transcriptional activity and vice versa.^[@bib15]^ Most GBMs harbor p53 mutations, which are considered critical in GBM development^[@bib16]^ and p53 rescue compounds induce p53-dependent growth arrest and sensitizes glioma cells to Apo2L/TRAIL-induced apoptosis.^[@bib17]^

SIRT1 an NAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase, known to decrease transcriptional activity of p53,^[@bib18]^ is a component of CK2-regulated anti-apoptotic network.^[@bib19]^ Silencing of SIRT1 enhances sensitivity of glioblastoma to radiotherapy.^[@bib20]^ Accordingly, we investigated whether CK2-Is could sensitize glioma cells to TNF*α*-induced apoptosis through regulation of molecules associated with cell survival and resistance to apoptosis such as NF-*κ*B, p53 and SIRT1.

Results
=======

Elevated CK2 levels in glioblastoma biopsy samples
--------------------------------------------------

Though the ability of CK2 inhibitor to regulate DNA damage repair response and induce antitumor activity in a mouse xenograft model of human glioblastoma has been reported,^[@bib21]^ nothing is known about the status of CK2 in human glioma samples. We therefore investigated the status of CK2 in GBM tumors. Immunohistochemistry (IHC) revealed an elevated expression of CK2*α* in GBM tumors as compared with adjacent normal tissues ([Figure 1a](#fig1){ref-type="fig"}). Western blot analysis also confirmed an increased CK2*α* expression in glioma tissue as compared with the surrounding non-neoplastic tissue ([Figure 1b](#fig1){ref-type="fig"}).

CK2 regulates glioma cell viability and confers resistance to TNF*α*--induced apoptosis
---------------------------------------------------------------------------------------

As CK2 levels were elevated in GBM samples, we investigated its role in glioma cell survival and resistance to apoptosis. Although treatment with 20 *μ*M of DRB had no effect on cell viability, ∼20--30% reduction in viability was observed upon treatment with 40, 60 and 80 *μ*M of DRB, respectively ([Figure 1c](#fig1){ref-type="fig"}). Although treatment with TNF*α* alone had no effect on viability of glioma cells, co-treatment with 20, 40, 60 and 80 *μ*M of DRB resulted in ∼30--65% decrease in viability, as compared with control ([Figure 1c](#fig1){ref-type="fig"}). Similarly, Apigenin also affected cell viability ([Figure 1c](#fig1){ref-type="fig"}). Thus, both DRB and Apigenin sensitized glioma cells to TNF*α*-induced apoptosis. We chose 40 μM concentration of DRB and Apigenin for subsequent treatments. To further confirm CK2-I-mediated apoptotic death, TUNEL assay was performed ([Figure 1d](#fig1){ref-type="fig"}). The 15--25% increase in TUNEL-positive cells observed upon DRB and Apigenin treatment was further elevated to ∼ 50--60% when DRB or Apigenin was co-administered with TNF*α* ([Figure 1d](#fig1){ref-type="fig"}). To further confirm the involvement of CK2 in glioma cell survival, viability of cells transfected with small interfering RNAs (siRNAs) against *α* and *β* subunit of CK2, both in presence and absence of TNF*α* was determined. The 20--25% decrease in cell viability observed upon siRNA-mediated knock-down of CK2 *α*/*β* subunits was further elevated to 30--40% in the presence of TNF*α* ([Figure 1e](#fig1){ref-type="fig"}).

The significant 1.3, 1.5 and 1.7-fold increase in caspase-3 activity observed in U87MG, A172 and T98G cells upon treatment with DRB, respectively, was further elevated to 2.9, 3.2 and 4.0-fold in the presence of TNF*α*. Similar activation of caspase-3 was also observed in cells treated with Apigenin either alone or in combination with TNF*α* ([Figure 1f](#fig1){ref-type="fig"}).

CK2-I-mediated apoptosis does not involve caspase-8 activation
--------------------------------------------------------------

Interaction of Fas with FADD recruits procaspase-8 that induces subsequent caspase-8 and caspase-3 activation leading to apoptosis. Although CK2 inhibition is known to trigger apoptosis through FADD and caspase-8,^[@bib22]^ CK2-Is had no effect on FAS or FADD expression ([Figure 2a](#fig2){ref-type="fig"}) or caspase-8 activity ([Figure 2b](#fig2){ref-type="fig"}) in glioma cells, both in presence and absence of TNF*α*. To further confirm the role of caspase-8, the viability of cells treated with different combinations of TNF*α* and CK2-I in the presence and absence of caspase-8 inhibitor was determined. CK2-I-mediated decrease in cell viability remained unaffected in the presence of caspase-8 inhibitor ([Figure 2c](#fig2){ref-type="fig"}). This ruled out the possible involvement of caspase-8 in CK2-I-induced apoptosis.

CK2-Is abrogate TNF*α* induced NF-*κ*B activity in glioma cells
---------------------------------------------------------------

CK2 is known to regulate NF-*κ*B through regulation of IKK.^[@bib23]^ Treatment with CK2 inhibitors decreased TNF*α*-induced pI*κ*K*α*/*β* level in glioma cells ([Figure 2d](#fig2){ref-type="fig"}). This decrease was concomitant with increase in I*κ*B*α* and decrease in NF-*κ*B levels ([Figure 2d](#fig2){ref-type="fig"}). As CK2-I prevents NF-*κ*B activation,^[@bib11]^ we investigated whether CK2-Is increase sensitivity to TNF*α*-induced apoptosis through inhibition of NF-*κ*B activity. Transfection of glioma cells with NF-*κ*B luciferase reporter followed by TNF*α* treatment demonstrated ∼9--11-fold increase in luciferase activity over the vector control ([Figure 2e](#fig2){ref-type="fig"}). Although treatment with DRB or Apigenin alone had no significant effect on NF-*κ*B activity, CK2-Is reduced TNF-induced NF-*κ*B activity to levels comparable to control ([Figure 2d](#fig2){ref-type="fig"}). Similar decrease in TNF*α*-induced NF-*κ*B luciferase activity was observed in cells transfected with CK2*α*/*β* siRNAs ([Figure 2f](#fig2){ref-type="fig"}), confirming the involvement of CK2 in TNF*α*-induced aberrant NF-*κ*B activation.

CK2-Is increases p53 expression in glioma cells
-----------------------------------------------

As TNF*α*-activated NF-*κ*B represses p53 transcriptional activity and vice versa,^[@bib15]^ and as CK2-Is decreased TNF*α*-induced NF-*κ*B activation, we determined p53 status in CK2-I- and TNF*α*-treated cells. A dramatic increase in p53 levels accompanied with an increase in phosphorylation (Ser-15) and acetylation (Lys373, 382) of p53 was observed upon treatment with CK2-Is either alone or in the presence of TNF*α* ([Figure 3a](#fig3){ref-type="fig"}). This increase was greater in p53 wild-type (U87MG and A172) cells as compared with the slight increase observed in p53 mutant (T98G) cells. Though A172 is known to be a p53 mutant cell line,^[@bib24]^ sequencing of DNA-binding region of p53 suggested it to be p53 wild type for DNA-binding domain. p53 status in the glioma cell lines was confirmed by sequencing ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

CK2 inhibition increases DNA-binding ability and transcriptional activity of wild-type p53
------------------------------------------------------------------------------------------

Further, we went on to investigate the effect of CK2-I-mediated increase in p53 phosphorylation and acetylation on its functional activity. Although CK2-Is increased DNA-binding ability of p53 in U87MG and A172 by ∼ 2--4-fold either alone or in combination with TNF*α*, it had no significant effect on the binding ability of mutant p53 in T98G cells ([Figure 3b](#fig3){ref-type="fig"}). This suggested that CK2 inhibition restores the function of wild-type p53 independent of TNF*α*. Similarly, although a ∼2--3-fold increase in p53 transcriptional activity was observed in CK2-I-treated U87MG and A172 cells, its activity remained unaltered in T98G cells ([Figure 3c](#fig3){ref-type="fig"}). This CK2-I-induced increase in p53 DNA-binding ability and transcriptional activity in U87MG and A172 cells was significantly reduced in the presence of p53 inhibitor, Pifithrin-*α* ([Figures 3b and c](#fig3){ref-type="fig"}). The relevance of CK2 in the activation of p53 function was further confirmed in U87MG and A172 cells, where siRNA-mediated knockdown of CK2*α*/*β* increased p53 transcriptional activity ([Figure 3d](#fig3){ref-type="fig"}).

CK2-I-mediated increased p53 activity reduces glioma cells viability
--------------------------------------------------------------------

To establish the functional significance of this increased p53 levels, we determined the viability of CK2-I-treated glioma cells in the presence of TNF*α*, p53 inhibitor Pifithrin-*α* or both. The 50% decrease in cell viability observed in U87MG and A172 upon treatment with TNF*α* and DRB was significantly reduced to ∼25% when TNF*α* and CK2-I treatment was supplemented with Pifithrin-*α* ([Figure 3e](#fig3){ref-type="fig"}). Similar results were obtained with Apigenin also. This ability of Pifithrin-*α* to reverse TNF*α* and CK2-I-mediated decrease in cell viability indicated the involvement of p53 in CK2-I-induced cell death in p53 wild-type glioma cells. However, ability of Pifithrin-*α* to reverse TNF*α-* and CK2-I-mediated cell death in p53 mutant T98G cells was not significant ([Figure 3e](#fig3){ref-type="fig"}). Similarly, siRNA-mediated p53 knockdown was able to rescue CK2-I-induced cell death both in the presence and absence of TNF*α* in p53 wild-type glioma cells only ([Figure 3f](#fig3){ref-type="fig"}). These results confirm the involvement of p53 in CK2-I-mediated glioma cell death.

p53 null cells are resistant to CK2-I-induced apoptosis
-------------------------------------------------------

To confirm the involvement of CK2-I-induced p53 activation in inducing apoptosis, the effect of CK2-I on the viability of p53 null cells H1229 and SaOS2 was investigated. Both the p53 null cell lines were resistant to CK2-I-induced apoptosis, as treatment with DRB and Apigenin failed to induce apoptosis in both these cells. However, CK2-I-mediated sensitization of p53 null cells to TNF*α* could have resulted from downregulation of NF-*κ*B activity ([Figure 3g](#fig3){ref-type="fig"}).

CK2-Is increase expression of p53 target genes associated with cell cycle regulation and apoptosis
--------------------------------------------------------------------------------------------------

We next investigated whether activation of p53 function induces genes that promote cell cycle arrest (p21and GADD45*β*) and apoptosis (Noxa). Although TNF*α* alone had no effect on p21, CK2-Is either alone or in combination with TNF*α* elevated p21 expression ([Figure 4a](#fig4){ref-type="fig"}). CK2-Is either alone or in combination with TNF*α* increased mRNA levels of p53-induced pro-apoptotic molecules GADD45*β* and Noxa ([Figure 4a](#fig4){ref-type="fig"}). This increase in p21, Noxa and GADD45*β* level was downregulated by Pifithrin-*α* ([Figures 4a and b](#fig4){ref-type="fig"}). No change in Noxa and GADD45*β* levels was observed in cells treated with TNF*α* alone ([Figure 4b](#fig4){ref-type="fig"}).

As changes in p21 expression indicated alteration in cell cycle progression, we performed FACS analysis to determine the cell cycle profile of glioma cells treated with different combination of CK2-Is, TNF*α* and Pifithrin*α*. Although TNF*α* had no significant effect on cell cycle progression, treatment with CK2-I induced G2/M arrest both in the presence and absence of TNF*α* ([Figure 4b](#fig4){ref-type="fig"}). A 5.4, 5.8, 15.3 and 14.3%, cells at G2/M phase was observed in control, TNF*α*, Apigenin, TNF*α* and Apigenin-treated A172 cells, respectively. Treatment with Pifithrin-*α* reversed CK2-I-induced cell cycle arrest ([Figure 4c](#fig4){ref-type="fig"}). Similar results were obtained in U87 cells also (data not shown).

CK2-Is induces telomere shortening and senescence in a p53-dependent manner
---------------------------------------------------------------------------

Activation of p53 leads to telomere shortening, and repression of human telomerase reverse transcriptase (hTERT) activity by p53 is mediated by p21.^[@bib25]^ As p53 and p21 levels were elevated in CK2-I-treated p53 wild-type cells, we determined hTERT activity in cells treated with CK2-Is or TNF*α* or both. Although CK2-Is decreased hTERT activity, this decrease was greater in the presence of TNF*α*. Importantly, CK2-I mediated reduction in hTERT activity was p53-dependent as the hTERT activity was reversed significantly in the presence of Pifithrin-*α* ([Figure 5a](#fig5){ref-type="fig"}).

As activation of p53-p21 pathway also acts as a major mediator of cellular senescence induced by CK2 inhibition,^[@bib26]^ we determined *β*-galactosidase activity in CK2-I-treated glioma cells. The increase in senescence-positive cells observed in cells treated with CK2-I ([Figure 5b](#fig5){ref-type="fig"}) both in the presence and absence of TNF*α* ([Figure 5b](#fig5){ref-type="fig"}), was abrogated in the presence of Pifithrin-*α*.

CK2-I-mediated abrogation of NF-κB and increase in p53 activation are independent events
----------------------------------------------------------------------------------------

Given that TNF*α*-activated NF-*κ*B represses p53 transcriptional activity and vice versa,^[@bib15]^ we investigated whether elevated p53 levels could have resulted in decreased NF-*κ*B activation in cells treated with a combination of TNF*α* and CK2-Is. However, the ability of CK2-Is to downregulate TNF*α*-induced NF-*κ*B transcriptional activity was unaffected by Pifithrin-*α* ([Figure 5c](#fig5){ref-type="fig"}). Thus, p53 activation and NF-*κ*B downregulation in CK2-I- and TNF*α*-treated cells are two independent events.

CK2-Is differentially regulates expression of genes associated with apoptosis in TNF*α*-treated p53 wild-type and mutant glioma cells
-------------------------------------------------------------------------------------------------------------------------------------

To further establish which apoptosis-related genes were altered upon treatment with CK2 inhibitor, we performed a quantitative real-time PCR (qRT-PCR)-based apoptotic gene array analysis. We observed distinct patterns of gene expression in cells treated with either TNF*α* or Apigenin or both in p53 wild-type (A172) and mutant (T98G) glioma cells. In p53 wild-type A172 glioma cells, among the 84 genes tested, transcript levels of 20 genes were increased upon TNF*α* treatment and their increased levels were abrogated significantly with CK2-Is ([Table 1a](#tbl1){ref-type="table"}). Most of these anti-apoptotic genes are known to be regulated in TNF*α-* and NF-*κ*B-dependent manner (*TNFRSF9, TNFSF10, BIRC3, CD40, TNFRSF11B, RIPK2, BCL2L11, BID, BIK, XIAP, BNIP3, NOD1, CARD8, TNFRSF1A, CD70, TRADD, TRAF2, TRAF3, BCL2* and *BCLAF1*). Moreover, 10 genes (*BCL2L1, BCL2L10, PYCARD, APAF1, GADD45A, CIDEA, TNFRSF10A, CASP10, CASP14* and *CASP5*) were found to be upregulated by CK2-I independent of TNF*α* ([Table 1a](#tbl1){ref-type="table"}). Several of these genes were found to be p53-dependent pro-apoptotic factors. This indicated the importance of CK2-I-induced p53 in regulating the pro-apoptotic response.

On the other hand, in p53 mutant T98G cell lines, transcript levels of 10 TNF*α* and NF-*κ*B target genes (*BIRC3, TNFRSF9, RIPK2, BCL2A1, PYCARD, CFLAR, TRADD, TRAF2, TRAF3* and *CARD6*) were increased upon TNF*α* treatment and their increased levels were brought down significantly by CK2-I. Moreover, levels of four pro-apoptotic genes (*CASP10, CASP14, CASP5* and *CIDEA*) were upregulated upon CK2 inhibition. Similarly, transcript levels of four genes (*XIAP, BIRC6, NOL3* and *TRAF4*) were downregulated significantly upon CK2-I treatment either alone or in presence of TNF*α*. All of them are known apoptotic inhibitors ([Table 1b](#tbl1){ref-type="table"}).

CK2-I increases the stability of p53 by decreasing its ubiquitination
---------------------------------------------------------------------

As CK2-I induced p53 expression without effecting its transcript level ([Table 1](#tbl1){ref-type="table"}), we investigated whether CK2-I-mediated increase in p53 level was the consequence of increased stability of the p53 protein. The role of CK2 on p53 stability was determined by treating glioma cells with protein synthesis inhibitor, Cycloheximide (CHX), in the presence and absence of CK2-I. Although expression of p53 decreased rapidly after incubation with CHX in untreated cells, treatment with Apigenin prevented such degradation ([Figure 6a](#fig6){ref-type="fig"}). This suggested increased stabilization of p53 upon CK2 inhibition.

Decreased MDM2--p53 association upon CK2 inhibition leads to p53 stabilization
------------------------------------------------------------------------------

Ubiquitin ligase MDM2 negatively regulates p53 stability by promoting its ubiquitin-mediated degradation^[@bib27]^ and CK2 is known to regulate p53 turnover through MDM2.^[@bib28]^ We therefore investigated whether CK2-mediated stabilization of p53 is MDM2-dependent. As no change in MDM2 levels was observed upon treatment of glioma cells with CK2-I, both in the presence and absence of TNF*α* (data not shown), we investigated whether CK2-Is alter the association of p53 with MDM2. Association of p53 with MDM2 decreased upon CK2-I treatment ([Figure 6b](#fig6){ref-type="fig"}). It is possible that decreased MDM2--p53 association prevents rapid degradation of p53, leading to its accumulation in CK2-I-treated glioma cells. This decreased MDM2--p53 interaction was concomitant with decrease in p53 ubiquitination, suggesting that CK2-I increases p53 levels by preventing ubiquitin-mediated p53 degradation ([Figure 6b](#fig6){ref-type="fig"}).

CK2 regulates SIRT1 activity in glioma cells
--------------------------------------------

As CK2 regulate p53 activity through SIRT1-dependent deacetylation^[@bib18]^ and as we have observed increased p53 acetylation upon CK2-I treatment, we determined SIRT1 activity in cells treated with CK2-Is both in the presence and absence of TNF*α*. A ∼30--40% decrease in SIRT1 activity was observed in CK2-I-treated cells independent of TNF*α* ([Figure 7a](#fig7){ref-type="fig"}).

Elevated SIRT1 levels in glioma samples
---------------------------------------

As SIRT1 is associated with tumorigenesis and resistant to radio- and chemotherapy,^[@bib29]^ we determined its expression levels in GBM tumor samples as compared with adjacent normal tissue. We report for the first time an elevated expression of SIRT1 in GBM tumor samples as compared with the surrounding non-neoplastic tissue, as demonstrated by IHC and western blotting ([Figure 7b](#fig7){ref-type="fig"}).

Role of SIRT1 in CK2-I-induced p53-dependent glioma cell apoptosis
------------------------------------------------------------------

In order to confirm the involvement of CK2-I-induced decrease in SIRT1 activity on glioma cell proliferation, we determined viability of cells over-expressing WT-SIRT1 in the presence and absence of CK2-Is. Over-expression of SIRT1 significantly prevented CK2-I-induced apoptosis both in the presence and absence of TNF*α* ([Figure 7c](#fig7){ref-type="fig"}).

As SIRT1 regulates p53,^[@bib18]^ we next investigated the role of SIRT1 in CK2-I-induced p53 transcription activity in cells transfected with WT-SIRT1 in the presence and absence of CK2-Is and TNF*α*. Increase in p53 transcriptional activity observed upon treatment with CK2-I was abrogated upon SIRT1 over-expression ([Figure 7d](#fig7){ref-type="fig"}). These results clearly suggested the involvement of SIRT1 in the regulation of CK2-I-induced p53 activation and subsequent decrease in glioma cells viability.

Discussion
==========

Casein kinase-2 is reported to have a role in overcoming resistance of glioma cells towards radiation therapy.^[@bib30]^ Moreover, CK2-Is target NF-*κ*B signaling^[@bib11]^ and as inactivation of NF-*κ*B sensitizes glioma cells to TNF*α*-induced apoptotic cell death.^[@bib2],\ [@bib3]^ These findings compelled us to investigate whether inhibition of CK2 could sensitize glioma cells to TNF*α*-induced apoptosis. We report for the first time an elevated expression of CK2 in GBM tumors as compared with the surrounding non-neoplastic tissue. Our studies indicate that CK2-Is DRB and Apigenin as well as CK2 siRNA sensitizes glioma cells to TNF*α*-induced cell death. Though CK2 inhibitor trigger apoptosis through FADD and caspase-8,^[@bib22]^ neither DRB nor Apigenin increased Fas or FADD expression or utilized caspase-8-mediated signaling to induce glioma cell death. CK2 is known to regulate TNF*α*-dependent NF-*κ*B activity,^[@bib31]^ and similarly in glioma cells, treatment with both DRB and Apigenin abrogated TNF*α*-induced NF-*κ*B activation.

CK2 inhibition in glioma cells triggered activity of wild-type p53 as evidenced by increased p53 levels, its phosphorylation and acetylation, DNA-binding ability and transcriptional activation. However, CK2-I failed to affect the functionality of mutant p53. It is known that receptor-interacting protein 1, which is a critical component of NF-*κ*B signaling, inhibits p53 function through NF-*κ*B activation in glioblastoma.^[@bib32]^ It is possible that although CK2-I-induced p53 activation triggered cell death, it was the ability of CK2-Is to inhibit TNF*α*-induced NF-*κ*B activation that lead to synergistically enhanced cell death in the presence of TNF*α*. Restoration of p53 function by CK2-Is was accompanied by elevated expression of p53 target genes p21, NOXA and GADD45*β* that are associated with apoptosis and cell cycle arrest. The results of gene expression profiling suggested differential responsiveness of p53 wild-type and mutant cells to CK2 inhibition, in terms of the expression of genes that are known p53 targets, as well as those relevant for the activation of caspases and induction of TNF*α*-mediated apoptosis. Gene profiling array also confirmed our observation that CK2 inhibition does not involve caspase-8, as no change in its levels was observed in cells treated with TNF*α* in the presence of Apigenin. Though CK2-I had no effect on the expression of p53 mRNA levels as demonstrated by the PCR array, it increased the stability of p53 protein by decreasing its ubiquitination and interaction with MDM2 to prevent subsequent degradation.

The decrease in SIRT-1 activity in glioma cells upon CK2 inhibition was associated with p53 activation, as over-expression of SIRT1 prevented CK2-I-mediated increase in p53 transcriptional activation. This was not surprising as CK2 regulates p53 activity directly and indirectly through SIRT-1.^[@bib19]^ Importantly, SIRT1 over-expression rescued glioma cells from CK2-I-induced apoptosis. An increase in senescence was also observed in CK2-I-treated cells. It is possible that decrease in SIRT1 activity lead to senescence, as induction of senescence-like growth arrest in human breast and lung cancer cells by Sirtinol-- a specific inhibitor for SIRT1 has been reported.^[@bib33]^ Given that both CK2 and SIRT1 are elevated in GBM and their downregulation is concomitant with apoptosis and senescence, our study suggests that targeting CK2-SIRT1 nexus might shed light on how CK2 regulates glioma progression.

Our studies indicate that CK2 inhibitor (i) sensitizes glioma cells to TNF*α*-induced apoptosis in an caspase-8-independent manner (ii) decreases TNF*α*-induced NF-*κ*B activation (iii) reactivates wild-type p53 function (iv) inhibits SIRT1 activity (v) inhibits telomerase activity and (vi) induces senescence ([Figure 8](#fig8){ref-type="fig"}). Taken together, CK2-I sensitizes both p53 wild-type and mutant glioma cells to TNF*α*-induced apoptosis. Depending on the p53 status, this is achieved by CK2-Is either through abrogation of NF-*κ*B activation and/or rescue of wild-type p53 function. Importantly, this ability of CK2-I to induce glioma cell death irrespective of p53 status may be of clinical significance for the treatment of glioma, where p53 mutation is considered critical for its progression.^[@bib16]^ Although activation of p53 triggers apoptosis, stimulation of NF-*κ*B promotes resistance to apoptosis. Interestingly, CK2-Is co-ordinate these two opposing events to overcome TNF*α*-induced resistance to apoptosis. As induction of both senescence and apoptosis in human cancer cells has been reported,^[@bib34]^ the ability of CK2-I to induce both these events to reduce cell viability warrants further investigation of CK2 as a potential anti-glioma target.

Materials and Methods
=====================

Processing of tissue and IHC
----------------------------

IHC was performed on tissue samples collected from patients with histologically confirmed GBM (*n*=19) to determine CK2 and SIRT1 expression as described.^[@bib35]^ Non-neoplastic brain tissue (*n*=7) obtained from margins of the tumors whenever possible was used as control. Samples were obtained as per the guidelines of Institutional Human Ethics Committee of NBRC.

Cell culture and treatment
--------------------------

Glioblastoma cell lines A172, U87MG and T98G were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM supplemented with 10% fetal bovine serum. On attaining semi-confluence, cells were switched to serum-free media (SFM) and after 12 h, cells were treated with different concentration of DRB or Apigenin (in Dimethyl sulphoxide, DMSO) or Pifithrin-*α* in the presence or absence of TNF*α* (50 ng/ml) in SFM for 24 h. DMSO-treated cells were used as controls. All reagents were purchased from Sigma unless otherwise stated. The p53 null cell lines H1229 and SaOS2 were a kind gift from Dr. Sanjeev Das, National institute of Immunology, India.

Determination of cell viability
-------------------------------

Viability of cells treated with different combinations of TNF*α*, CK2-Is and Pifithrin-*α* for 24 h in 96-well plates was assessed using the MTS assay (Promega, Madison, WI, USA) as described.^[@bib36]^ Values were expressed as a percentage relative to those obtained in controls.

Western blot and immunoprecipitation
------------------------------------

Protein was isolated from whole-cell lysates and nuclear extracts from cells treated with different combinations of TNF*α*, CK2-Is and Pifithrin-*α* and western blot was performed as described.^[@bib37]^ The following antibodies were used: p21 (BD Biosciences, San Diego, CA, USA), ~p~p53 ser15, MDM2, SIRT1 (Abcam, Cambridge, UK), acetylated p53 lys373, lys382 (Millipore, Temecula, CA, USA), pIKK*α*/*β* (Ser176/180), I*κ*B*α*, p53 (Cell Signaling, Danvers, MA, USA), Ub (Dako, Glostrup, Denmark) CK2*α*, Fas and FADD, p53, p65, c23, GAPDH. Antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) unless otherwise mentioned. Secondary antibodies were purchased from Vector Laboratories Inc. (Burlingame, CA, USA). The blots were stripped and re-probed with anti-*β*-actin (Sigma, St. Louis, MO, USA) to determine equivalent loading as described.^[@bib37]^ Immunoprecipitation was performed with p53 antibody to determine the association of p53-MDM2 as described.^[@bib38]^

Assay of caspase-3 and 8 activities
-----------------------------------

The Colorimetric Assay kits for caspases-3 and 8 (Sigma) were used to determine the enzymatic activity of caspases in cells treated with different combinations of TNF*α* and CK2-Is as described.^[@bib39]^

*Luciferase* reporter gene assay
--------------------------------

Reporter assay in cells transfected with p53 or NF-*κ*B luciferase or WT SIRT1 constructs, and treated with different combinations of TNF*α*, CK2-Is and Pifithrin-*α* was performed as described.^[@bib37]^ The p53 luciferase and SIRT1 constructs were obtained from Addgene (Cambridge, MA, USA) and NF-*κ*B luciferase construct obtained from Clontech (Madison, WI, USA).

siRNA transfection
------------------

Before 18 h of transfection, 3 × 10^4^ cells were seeded onto 24-well plates in medium without antibiotics and transfection with 50 nmol/l duplex CK2*α*, CK2*β*, p53 or non-specific siRNA (Thermo Fischer Scientific, Lafayette, CO, USA) was carried using Lipofectamine RNAi Max reagent (Life Technologies-Invitrogen, Carlsbad, CA, USA) as described.^[@bib40]^

p53 DNA-binding assay
---------------------

DNA-binding activity of p53 was measured with the DuoSet IC (IntraCellular) Assay Development System (R&D Systems, Minneapolis, MN, USA) according to manufacturer\'s instructions.

Telomerase activity
-------------------

Telomerase activity of cells treated with TNF*α* in the presence and absence of CK2-Is and Pifithrin-*α* was determined using the *T*elo*TAGGG* Telomerase PCR ELISA Plus kit (Roche Diagnostics, Mannheim, Germany) as described.^[@bib39]^

Flow cytometric analysis of DNA content
---------------------------------------

FACS analysis was performed to determine the effect of TNF*α* or Apigenin or both in the presence and absence of Pifithrin *α* on cell cycle progression of glioma cells, using Cell Quest program on FACS Calibur (Becton Dickinson, San Diego, CA, USA) as described.^[@bib5]^ Results were analyzed using Cell Quest pro software (Becton Dickinson).

Senescence-associated *β*-gal staining
--------------------------------------

Cells treated with CK2-Is either alone or in presence of TNF*α* and/or Pifithrin were stained with the senescence-associated *β*-galactosidase (SA-*β*-gal) staining solution (Sigma) as per the manufacturer\'s instructions. The numbers of blue-stained (SA-*β*-gal-positive) cells and total cells were counted microscopically and percentage of SA-*β*-gal-positive cells was calculated.

SIRT1 activity assay
--------------------

Deacetylase activity of SIRT1 was measured with SIRT1 activity assay kit from Calbiochem (Merck KGaA, Darmstadt, Germany) according to manufacturer\'s instructions.

RT-PCR and human apoptosis qRT-PCR array
----------------------------------------

RT-PCR analyses for NOXA and GADD45*β* expression in cells treated with different combinations of TNF*α* and CK2-Is was performed as described.^[@bib37]^ PCR primers for NOXA and GADD45*β* are listed in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. qRT-PCR was performed using an apoptosis PCR Array containing 84 apoptosis-related genes (SuperArray Biosciences, Frederick, MD, USA) as per manufacturer\'s instruction. Briefly, total RNA samples from TNF*α* and Apigenin-treated A172 and T98G glioma cells were isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). An equal amount of RNA (2 *μ*g) was used for reverse transcription using RT2 First Strand Kit (SuperArray Biosciences). PCR reactions were done using the RT2 profiler PCR array PAHS-012 (Human Apoptosis PCR Array) on the ABI 7500 using RT2 Real-time SYBR Green PCR master mix PA-012. The total volume of the PCR reaction was 25 *μ*l. The thermocycler parameters were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Five housekeeping genes were included on the array (*B2M, HPRT1, RPL13A, GAPDH,* and *ACTB*) to normalize the transcript levels. Results were analyzed as per user manual guidelines using integrated web-based software package for the PCR Array System (SuperArray Biosciences RT2 Profiler PCR Array Human Apoptosis PAHS-012--A-12).

Statistical analysis
--------------------

All comparisons between groups were performed using two-tailed paired student\'s *t*-test. All *P*-values \<0.05 were taken as significant.

The work was supported by a research grant from the Department of Biotechnology (DBT, Government of India \#BT/PR/12924/Med/30/235/2009). DD is supported by a research fellowship from Council of Scientific and Industrial Research (CSIR, Government of India).

CK2-I

:   casein kinase-2 inhibitor

NF-*κ*B

:   nuclear factor kappa B

SIRT1

:   sirtuin 1

TNF*α*

:   tumor necrosis factor alpha

GBM

:   glioblastoma multiforme

DRB

:   5,6-dichlorobenzimidazole 1-*β*\--ribofuranoside

CK2a/b siRNA

:   siRNA against a and b subunits of casein kinase-2

FADD

:   Fas-associated protein with death domain

I*κ*K

:   inhibitor of nuclear factor kappa B kinase

MDM2

:   murine double minute

NS siRNA

:   non-specific siRNA
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![CK2 inhibition sensitizes glioma cells to TNF*α*-induced apoptosis. (**a**) CK2 immuno-localization in glioma tumor samples. Cryosections of glioma and adjacent normal tissues were immunostained for CK2*α* as described in Materials and Methods. Images were taken at 40 × magnification. (**b**) Western blot analysis demonstrating elevated CK2*α* expression in GBM tumor as compared with surrounding non-neoplastic tissue. The figure shows blots from five independent tumor samples with identical results. (**c**) Viability of glioma cells treated with CK2-Is in the presence and absence of TNF*α* was determined by MTS assay. The graphs represent the viable glioma cells, percentage of control, upon treatment with 50 ng/ml TNF*α* either alone or in combination with different concentrations of DRB or Apigenin for 24 h. (**d**) The graphs represent percentage of TUNEL-positive glioma cells upon treatment with either DRB/Api or TNF*α* or both, as counted from multiple fields. (**e**) siRNA-mediated knockdown of CK2 decreases glioma cell viability as determined by MTS assay. The graph represents the viable glioma cells, percentage of control, transfected with CK2*α*/*β* siRNA when treated with TNF*α* for 24 h. Inset shows the knockdown efficiency of CK2 *α* siRNA. (**f**) Increase in caspase-3 activity in glioma cells treated with CK2-Is or TNF*α* or both, as determined by caspase-3 activity assay. Values (**c**--**f**) represent the means ±S.E.M. from three independent experiments. ^\*^Denotes significant change from control (*P*\<0.05)](cddis201210f1){#fig1}

![CK2 inhibitors abrogate TNF*α*-induced NF-*κ*B activation. (**a**) Fas and FADD expression in glioma cells treated with either TNF*α* or CK2-I or both for 24 h as demonstrated by western blot. A representative blot is shown from three independent experiments with identical results. Blots were reprobed for *β*-actin to establish equivalent loading. (**b**) Caspase-8 activity in glioma cells treated with CK2-Is or TNF*α* or both for 24 h, as determined by the caspase-8 activity assay kit. (**c**) The graph represents the viable cells, percentage of control, observed when glioma cells were treated with different combinations of TNF*α*, CK2-Is and caspase-8 inhibitor, as determined by MTS assay. (**d**) The levels of NF-*κ*B, pI*κ*K*α*/*β* and I*κ*B*α* in glioma cells, treated with either TNF*α* or CK2-Is or both, as demonstrated by western blot. A representative blot is shown from three independent experiments with identical results. Blots were reprobed for *β*-actin and c23 to establish equivalent loading. (**e**) DRB and Apigenin decreases TNF*α*-mediated NF-*κ*B activation in glioma cells. The graph represents fold change in NF-*κ*B luciferase activity over control, in cells treated with TNF*α* in the presence and absence of CK2-Is. (**f**) siRNA-mediated knockdown of CK2*α*/*β* decreases TNF*α*-induced NF-*κ*B activation in glioma cells. Values in (**b**, **c**, **e** and **f**) represent the mean ±S.E.M. from three independent experiments. ^\*^Denotes significant change from control (*P*\<0.05), ^\#^denotes significant change from TNF*α*. T, D and A denote TNF*α*, DRB and Apigenin, respectively](cddis201210f2){#fig2}

![CK2 inhibition triggers p53 expression and activation to induce glioma cell death. (**a**) Western blot indicated phosphorylated, acetylated and total p53 levels in cells treated with CK2-Is in the presence and absence of TNF*α*. A representative blot is shown from three independent experiments with identical results. c23 was used as loading control. (**b**) Increased binding of p53 to its DNA-binding sequence in cells treated with CK2-Is, either alone or in combination with TNF*α*, is abrogated by p53 inhibitor, Pifithrin-*α*, The graphs represent relative binding activity of p53 under different conditions, as compared with untreated controls. Values represent means ±S.E.M. from three individual experiments. (**c**) CK2-I-mediated increase in p53 transcriptional activity is abrogated upon p53 inhibition. The graphs represent fold change in p53 luciferase reporter activity over control in cells treated with different combinations of CK2-Is, TNF*α* and Pifithrin-*α* for 12 h. (**d**) siRNA-mediated knockdown of CK2 *α*/*β* induces p53 transcriptional activity in p53 wild-type but not in mutant cell lines. The graph represents fold change in p53 luciferase reporter activity over NS-siRNA-transfected control. (**e**) CK2-I-mediated sensitization of glioma cells to TNF*α*-induced death is reversed by Pifithrin-*α* and (**f**) p53 siRNA. The graphs represent percentage viable glioma cells treated with different combinations of CK2-Is, TNF*α* and Pifithrin-*α* for 24 h, as determined by MTS assay. (Inset) p53 siRNA abrogates CK2-I-induced p53 levels as determined by western blot analysis. (**g**) CK2-I reduced viability of p53 null cells lines only in presence of TNF*α*. The graph represents percentage viable SAOS2 and H1299 cells treated with different combinations of CK2-Is and TNF*α*. Values in (**b**--**g**) represent the means ± S.E.M. from three independent experiments. ^\*^Denotes significant change from untreated control, ^\#^denotes significant change from CK2-I-treated cells either alone or in presence of TNF*α* (*P*\<0.05)](cddis201210f3){#fig3}

![CK2 inhibitor affects p53 target genes associated with cell cycle regulation and apoptosis. (**a**) CK2-I increases p21 expression in a p53-dependent manner. Representative blot is shown from three independent experiments with identical results. Blots were re-probed with c23 to establish equivalent loading. (**b**) CK2-I increases mRNA levels of pro-apoptotic molecules Noxa and GADD45*β* in a p53-dependent manner. Total RNA was isolated from cells treated with different combinations of TNF*α* and CK2-I, and the mRNA levels for Noxa, GADD45*β* and constitutive enzyme GAPDH were determined by RT-PCR. (**c**) Pifithrin-*α* reverses CK2-I-mediated G2/M phase arrest in A172 cells. FACS analysis was performed on A172 cells treated with different combinations of TNF*α*, CK2-Is and Pifithrin-*α*. Inset indicates percentage of cells in G1, S and G2/M phase of the cell cycle. C, T, Pf and A denote control, TNF*α*, Pifithrin-*α* and Apigenin, respectively](cddis201210f4){#fig4}

![CK2 inhibition-induced p53 activation decreases telomerase activity and induces senescence but has no effect on NF-*κ*B activity. (**a**) CK2-Is decrease telomerase activity in glioma cells in a p53-dependent manner. Glioma cells were treated with TNF*α* in the presence or absence of CK2-Is and/or Pifithrin-*α*; and *T*elo*TAGGG* Telomerase PCR ELISA was performed. Values represent the means±S.E.M. from three independent experiments. (**b**) CK2-I-induced senescence in glioma cells is p53-dependent as evident from senescence-specific *β*-gal staining. Images were taken at 20 × magnification. The graph represents fold increase in *β*-gal-positive cells upon treatment with different combinations of Apigenin, TNF*α* and Pifithrin-*α*. (**c**) Pifithrin-*α* does not affect the ability of DRB to abrogate TNF*α*-induced NF-*κ*B activation. The graph represents fold change in NF-*κ*B luciferase activity over control, in cells treated with different combinations of TNF*α*, DRB and Pifithrin-*α*. Values in (**a**--**c**) represent the means ± S.E.M. from three independent experiments. ^\*^Denotes significant change from control (*P*\<0.05), ^\#^denotes significant change from CK2-I-treated cells (*P*\<0.05)](cddis201210f5){#fig5}

![CK2 inhibition leads to p53 protein stabilization. (**a**) CK2-I prevents degradation of p53. Glioma cells, either untreated or treated with Apigenin for 12 h were further treated with CHX for the indicated times. Western blot analysis was performed to determine p53 levels in the lysates. Representative blot is shown from three independent experiments with identical results. Blots were reprobed for GAPDH to establish equivalent loading. Densitometric analysis shows p53 levels upon CHX treatment in the presence and absence of Apigenin. (**b**) CK2-I decreases MDM2--p53 interaction and p53 ubiquitination in glioma cells. Lysates from cells treated with Apigenin were immunoprecipitated with p53 and probed with antibodies against MDM2 and ubiquitin. IgG levels are shown to establish equivalent loading. Representative blot is shown from two independent experiments with identical results. ^\*^Denotes significant change from control (*P*\<0.05)](cddis201210f6){#fig6}

![CK2 inhibitor-mediated downregulation of SIRT1 activity regulates p53. (**a**) CK2-Is decrease SIRT1 activity in glioma cells both in the presence and absence of TNF*α*. Glioma cells were treated with TNF*α* in the presence or absence of DRB/Api and subsequently SIRT1 activity was determined. Values represent the means±S.E.M. from three independent experiments. (**b**) SIRT1 immuno-localization in glioma tumor samples as revealed by IHC and western blot analysis. Cryosections of glioma and adjacent normal tissues were immunostained for SIRT1 as described in Materials and Methods. Images were taken at 40 × magnification. Western blot analysis also demonstrated elevated SIRT1 levels in GBM tumor as compared with surrounding non-neoplastic tissue. The figure shows blots from five independent tumor samples with identical results. (**c**) CK2-I-mediated decrease in SIRT1 activity regulates glioma cell viability. The viability of glioma cells transfected with SIRT1 over-expression vector and treated with Apigenin or TNF*α* or both for 24 h, was determined by MTS assay. The graph represents percentage viable cells of control. Inset shows the overexpressed SIRT1 levels as determined by immunoblotting. (**d**) CK2-I-mediated increase in p53 transcriptional activity is abrogated upon SIRT1 over-expression. Glioma cells co-transfected with SIRT1 over-expression vector and p53 luciferase reporter constructs were treated with Apigenin or TNF*α* or both and reporter assay was performed to determine p53 transcriptional activity. The graph represents fold change in p53 luciferase reporter activity over control. Values in (**a**, **c** and **d**) represent the means±S.E.M. from three independent experiments. ^\*^Denotes significant change from control (*P*\<0.05), ^\#^denotes significant decrease from mock-transfected CK2-I-treated cells (*P*\<0.05)](cddis201210f7){#fig7}

![Proposed model demonstrating the role of CK2 in glioma cell apoptosis and resistance to therapy. CK2 inhibition induces glioma cell death via activation of p53 through SIRT1 inhibition and sensitizes glioma cell to TNF*α* via downregulation of TNF*α*-induced NF-*κ*B activity](cddis201210f8){#fig8}

###### (a) A172 fold change over control; (b) T98G fold change over control

               **TNF*μ***   **TNF+Api**   **Apigenin**
  ------------ ------------ ------------- --------------
  *(a)*                                   
   TNFRSF9     33.2205      2.5758        −1.6189
   TNFSF10     16.9592      −4.6428       −5.8159
   BIRC3       23.007       7.9723        1.5746
   CD40        14.1625      6.8924        2.6945
   TNFRSF11B   4.9383       −5.6178       −6.8448
   RIPK2       2.0907       −1.7839       −3.0001
   BCL2L11     1.9507       −3.3058       −3.5186
   BIK         3.2021       1.7171        1.366
   XIAP        1.3186       −1.7777       −2.3376
   BNIP3       1.5147       −1.7593       −1.8987
   NOD1        1.9372       1.1447        −1.0755
   CARD8       1.433        −1.834        −2.7132
   TNFRSF1A    1.428        −4.3169       −3.4702
   CD70        1.8519       −1.6702       −2.8779
   TRADD       1.6748       −2.4284       −3.5925
   TRAF2       2.7397       1.3996        −1.5746
   TRAF3       1.9106       1.3472        −1.257
   BCL2        1.4835       −1.3472       −3.1821
   BCLAF1      1.458        −2.0491       −1.9319
   BCL2L1      1.1321       10.7034       4.976
   BCL2L10     1.8013       14.4701       11.2356
   PYCARD      1.9711       10.2319       5.3517
   APAF1       1.1559       6.8211        5.5022
   GADD45A     2.1947       12.3805       8.6939
   CIDEA       3.093        10.8528       6.0002
   TNFRSF10A   3.1799       14.1232       10.2674
   CASP10      1.7459       6.9886        5.5597
   CASP14      3.4319       15.455        10.6664
   CASP5       1.7279       5.2964        5.5597
   BIRC6       1.1761       −6.2333       −4.8736
   CRADD       1.2008       −3.1167       −3.2603
   CARD6       1.1966       −4.7076       −5.716
   BAG4        1.1088       −2.0139       −2.6117
   DAPK1       −1.17        −2.6299       −2.7321
   TP53        2.157        −1.25         −1.48
                                           
  *(b)*                                   
   BIRC3       22.28        3.2           1.04
   TNFRSF9     33.54        3.71          1.1
   RIPK2       6.91         2.2           1.52
   BCL2A1      2.88         1.36          1.16
   PYCARD      2.08         −1.26         −1.65
   CFLAR       2.05         −1.85         −1.3
   TRADD       1.88         −2.33         −1.49
   TRAF2       1.85         −1.29         1.46
   TRAF3       2.41         1.39          1.45
   CARD6       1.62         −1.65         −1.15
   XIAP        1.39         −1.75         −1.19
   BIRC6       1.21         −2.01         −1.22
   NOL3        1.06         −3.68         −1.15
   TRAF4       1.16         −2.07         −1.58
   CASP10      2.36         7.36          4.77
   CASP14      −1.16        13.93         14.87
   CASP5       −1.67        5.43          9.67
   CIDEA       1.3          2.66          6.34
   TP53        1.2          1.01          1.25

Abbreviation: TNF, tumor necrosis factor.

Quantitative real-time PCR to evaluate the relative transcript levels of a panel of 84 genes associated with apoptosis in cells treated with different combinations of CK2 inhibitor and TNF*α*. Gene expression profiling of mRNA isolated from glioma cells - A172 ([Table 1a](#tbl1){ref-type="table"}) and T98G ([Table 1b](#tbl1){ref-type="table"}), treated with TNF*α* in the presence and absence of Apigenin, was analyzed by quantitative PCR for genes involved in apoptotic pathways. Expressions of several genes affected by the treatments are shown. Table represents the average data from two independent experiments
